Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Epeleuton - Afimmune

Next Previous
Drug Profile

Epeleuton - Afimmune

Alternative Names: 15-HEPE; 5-hydroxyeicosapentaenoic acid; AF-102 - Afimmune; DS 102

Latest Information Update: 31 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator DS Biopharma
  • Developer Afimmune; DS Biopharma
  • Class Anti-inflammatories; Antianaemics; Antifibrotics; Antihyperglycaemics; Hepatoprotectants; Pentanoic acids; Vascular disorder therapies
  • Mechanism of Action 5-lipoxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sickle cell anaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alcoholic hepatitis; Chronic obstructive pulmonary disease; Diabetic neuropathies; Hypertriglyceridaemia; Idiopathic pulmonary fibrosis; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Sickle cell anaemia; Type 2 diabetes mellitus
  • Preclinical Atherosclerosis; COVID 2019 infections
  • No development reported Hepatic fibrosis

Most Recent Events

  • 09 Dec 2023 Pharmacodynamics data from a preclinical trial in Sickle cell disease presented at the 65th American Society of Hematology Annual Meeting (ASH-2023)
  • 08 Nov 2023 Epeleuton - Afimmune receives Fast Track designation for Sickle cell anaemia [PO,Capsule] in USA
  • 08 Nov 2023 Epeleuton receives Rare pediatric disease status for Sickle cell anaemia [PO,Capsule] in USA
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top